Journal article
Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial
F&S Reports (Online), Vol.1(3), pp.257-263
12/2020
DOI: 10.1016/j.xfre.2020.09.010
PMCID: PMC8244378
PMID: 34223253
Abstract
To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial.
Cost minimization analysis of trial results.
Thirty-one fertility centers.
Six hundred and nineteen women with serum antimüllerian hormone ≥5 ng/mL.
Controlled ovarian stimulation with HP-hMG or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist assisted reproduction cycle where fresh transfer of a single blastocyst was performed unless ovarian response was excessive whereupon all embryos were cryopreserved and patients could undergo subsequent frozen blastocyst transfer within 6 months of randomization.
Mean cost of achieving live birth after first transfer (fresh or frozen).
First-transfer efficacy, defined as live birth after first fresh or frozen transfer, was 54.5% for HP-hMG and 48.0% for recombinant FSH (difference 6.5%). Average cost to achieve a live birth after first transfer (fresh or frozen) was lower with HP-hMG compared with recombinant FSH. For fresh transfers, the cost was lower with HP-hMG compared with recombinant FSH. The average cost to achieve a live birth after first frozen transfer was also lower in patients treated with HP-hMG compared with recombinant FSH.
Treatment of predicted high-responders with HP-hMG was associated with lower cost to achieve a live birth after first transfer compared with recombinant FSH.
NCT02554279.
Details
- Title: Subtitle
- Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial
- Creators
- Jared C. Robins - Midwestern UniversityAndrew F. Khair - Ferring PharmaceuticalsEric A. Widra - Shady Grove Fertility CenterMichael M. Alper - Boston IVFWinnie W. Nelson - Ferring PharmaceuticalsEric D. Foster - Ferring PharmaceuticalsAnshul Sinha - Ferring PharmaceuticalsMasakazu Ando - Ferring PharmaceuticalsPatrick W. Heiser - Ferring PharmaceuticalsGaurang S. Daftary - Ferring Pharmaceuticals
- Resource Type
- Journal article
- Publication Details
- F&S Reports (Online), Vol.1(3), pp.257-263
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.xfre.2020.09.010
- PMID
- 34223253
- PMCID
- PMC8244378
- ISSN
- 2666-3341
- eISSN
- 2666-3341
- Language
- English
- Date published
- 12/2020
- Academic Unit
- Biostatistics
- Record Identifier
- 9984363572102771
Metrics
10 Record Views